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1. Introduction
   Infectious diseases have always been serious health 
problems with high morbidity and mortality in humans. 
Even though pharmaceutical companies have produced 
a number of new antibiotics in the past decade, 
resistance to these drugs has increased and has now 
become a global concern[1]. The global emergence of 
multi-drug resistant bacteria is increasingly limiting 
the effectiveness of current drugs and significantly 
causing treatment failure[2]. Staphylococcus aureus 
(S. aureus )  is  one of  the most  important  human 
pathogens associated with hospital and community-
acquired infections. Over the decades, the number 
and proportion of drug resistant pathogens, including 
methicillin-resistant S. aureus (MRSA), vancomycin-
resistant Enterococci, cephalosporin-resistant Klebsiella 
pneumonia, fluoroquinolone-resistant Pseudomonas 
PEER REVIEW                            ABSTRACT
KEYWORDS
Marine actinomycetes, Sponge-derived, Salinispora, Multi-drug resistant, Antibacterial, 
Rifamycin
Objective: To isolate, purify, characterize, elucidate structure and evaluate bioactive compounds 
from the sponge-derived Salinispora sp. FS-0034. 
Methods: The symbiotic actinomycete strain FS-0034 with an interesting bioactivity profile was 
isolated from the Fijian marine sponge Theonella sp. Based on colony morphology and obligatory 
requirement of seawater for growth, and mycelia morphological characteristics the isolate FS-0034 
was identified as a Salinispora sp. The bioactive compound was identified by using various 
spectral analysis of ultraviolet, high resolution electrospray ionization mass spectroscopy, 1H 
nuclear magnetic resonance, correlated spectroscopy and heteronuclear multiple bond coherence 
spectral data. A minimum inhibitory concentration assay were performed to evaluate the 
biological properties of the pure compound against multi-drug resistant pathogens.
Results: Bioassay guided fractionation of the ethyl acetate extract of the culture of Salinispora 
sp. FS-0034 by different chromatographic methods yielded the isolation of an antibacterial 
compound, which was identified as rifamycin W (compound 1). Rifamycin W was reported for 
its potent antibacterial activity against methicillin-resistant Staphylococcus aureus, wild type 
Staphylococcus aureus and vancomycin-resistant Enterococcus faecium and displayed minimum 
inhibitory concentrations of 15.62, 7.80 and 250.00 µg/mL, respectively.
Conclusions: The present study reported the rifamycin W from sponge-associated Salinispora 
sp. and it exhibited appreciable antibacterial activity against multi-drug resistant human 
pathogens which indicated that sponge-associated Actinobacteria are significant sources of 
bioactive metabolites.
Peer reviewer
Dr. Liu Ming, Key Laboratory of 
Experimental Marine Biology, Institute 
of Oceanology, Chinese Academy of 
Sciences (IOCAS), No. 7 Nanhai Road, 
Qingdao 266071, P.R. China.
Tel: +86-0532-82898893, 13589286247
E-mail: lmouc@hotmail.com
Comments
This is a good research paper in which 
the authors obtained rifamycin W 
(compound 1) from the EtOAc extract 
of the culture of Salinispora sp. 
FS-0034 and found that it had potent 
antibacterial activity. The results are 
meaningful and valuable and lay a 
solid foundation for further studies.
Details on Page 830
Article history:
Received 26 Dec 2013
Received in revised form 16 Apr, 2nd revised form 10 May, 3rd revised form 23 May 2014
Accepted 3 Jun 2014
Available online 13 Aug 2014
 Contents lists available at ScienceDirect
Satyendra Singh et al./Asian Pac J Trop Biomed 2014; 4(10): 825-831826
aeruginosa, multi-drug resistant Gram-negative bacteria 
and extensively drug resistant tuberculosis infections 
in different countries have increased due to the rise 
of epidemics in humans[3-5]. Consequently, new and 
innovative antimicrobial agents are urgently needed to 
combat these life threatening infections. 
   New trends in drug discovery from natural sources 
emphasize investigation on the marine ecosystem 
to explore numerous complex and novel chemical 
entities[6]. It is noteworthy that marine sources have 
also demonstrated tremendous abilities as producers 
of anticancer compounds and bioactive secondary 
metabolites which act against infectious diseases 
and inflammation[7]. Among the marine organisms, 
microbial-derived natural products are playing a 
significant role in the drug discovery process[8]. Marine 
Actinobacteria represent a rich source of new molecules with 
pharmacological properties, which are lead compounds for 
the development of new drugs[9,10]. Recently, sponge-
derived actinomycetes have been attracting increasingly 
interests as potential sources of unique and unusual 
bioactive secondary metabolites[11]. The isolation of 
secondary metabolite-producing bacteria from sponges 
and of microbial secondary metabolism gene clusters 
from the metagenome of sponges has led to the general 
understanding that these metabolites are, in many cases, 
the products of microbial symbionts and are not derived 
from the microbial diet of sponges[12]. In continuation of 
our studies on sponge-derived actinomycetes we now 
report on the bioactive compound against multi-drug 
resistant pathogens produced by Salinispora sp. isolated 
from the marine sponge Theonella sp. The goal of the 
present study is to isolate a bioactive compound showing 
antibacterial activities from the strain of Salinispora 
sp. FS-0034, which was isolated from the Fijian marine 
invertebrate.         
2. Materials and methods
2.1. General experimental procedures
   The ultraviolet  (UV)  spectrum was acquired in 
spectroscopy grade methanol using a PerkinElmer 
Lambda 35 spectrophotometer.  Nuclear magnetic 
resonance (NMR) experiments were performed on Varian 
Inova spectrometer 600 MHz. The chemical shifts were 
expressed in δ (ppm) and referred to the residual solvent 
(δH 2.50 ppm for dimethylsulfoxide-d6). High resolution 
electrospray ionization mass spectra (HRESIMS) were 
acquired by using an Agilent 1 100 series separations 
module equipped with an Agilent G1969A MSD (mass 
spectroscopy detector) in positive ion mode. Purification 
was done on a Zorbax ODS 5 µm 9.4 mm伊250 mm column. 
Analytical and semi-preparative high performance liquid 
chromatography (HPLC) was performed using a Waters 
515 pump connected to a 2487 UV-visible detector. Thin-
layer chromatography (TLC) analyses were carried out by 
using glass plate pre-coated silica gel 60 reversed phase 
(RP)-18 F254S (Merck, Darmstadt, Germany). Analytical 
grade solvents were utilized for TLC analysis. Burdick and 
Jackson high purity solvents were used for HPLC while 
Riedel-de Haen, Chromasolv liquid chromatography–
mass spectrometry (LC-MS) grade solvents were used for 
LC-MS. 
2.2. Sample collection and processing
   The sponge Theonella sp. was collected by hand using 
selfcontained underwater breathing apparatus at a depth 
of 10 m from Cicia, Lau group, Fiji Islands (17°47’33’’ S, 
179°23’94’’ W) in September 2008 during a three week 
biodiversity expedition in the central Lau Group. The 
sponge material was transferred into a sterilized bag 
immediately after harvesting and was transported cooled 
to the nearby laboratory. The isolation of bacteria was 
subsequently carried out. The sponge was identified 
by Dr. Paco Cardenas, Uppsala University, Sweden. A 
voucher specimen (G-0634) has been preserved at the 
Marine Reference Collection, The University of the 
South Pacific, Fiji Islands and at Georgia Institute of 
Technology, USA. 
   The sponge sample was rinsed three times with sterile 
seawater to eliminate nonspecific microbial propagules 
that stick to the sponge surface from the seawater, 
and the surface of the sponge tissue was subjected to 
surface-sterilization by using 70% ethanol under aseptic 
conditions. The surface sterilized sponge tissue was 
then cut into small pieces of approximately 0.1 cm3, 
homogenized and diluted with autoclaved membrane-
filtered seawater. The resulting homogenate was diluted 
with sterile seawater at three dilutions (1:10, 1:100, 
and 1:1 000). Hundred microliters of each dilution was 
plated onto A1 agar (10 g of starch, 4 g of yeast extract, 
2 g of peptone, 18 g of agar and 1 L of filtered natural 
seawater) medium. The isolation medium was amended 
with cycloheximide (100 µg/mL) and polymixin B (5 µg/mL) 
after autoclaving to avoid unwanted Gram negative bacteria 
and fungi contamination. The plates were incubated at 28 
°C for 3-4 weeks until the morphology of actinomycetes 
could be distinguished. 
2.3. Isolation of Salinispora strains 
   Actinomycetes were evaluated on each plate by eye 
and with the aid of an Olympus SZ51 binocular zoom 
stereomicroscope (8-40伊). Actinomycetes were recognized 
by the presence of filamentous hyphae, a characteristic 
that was just within the range of detection at the highest 
magnification used, and/or by the formation of tough, 
leathery colonies that adhered to the agar surface. 
Colonies were assigned to the genera Salinispora if, for 
larger colonies, they produced orange pigment, black 
spores that darkened the colony surface, and lacked 
areal hyphae. Smaller colonies, viewed microscopically, 
could be ascribed to the Salinispora group if they 
possessed finely branched, scattered hyphae that 
formed a moderately developed substrate mycelium as 
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described by Jensen, et al[13]. Salinispora-like colonies 
were successively transferred onto new media until pure 
cultures were obtained. All pure strains were grown 
in liquid culture and cryopreserved at -80 °C in 10% 
glycerol.
2.4. Seawater requirement test 
   The Salinispora strains were reported as the first 
obl igatory  mar ine  act inomycetes  which needed 
seawater for their growth[13,14]. Thus, all of the isolated 
Salinispora-like actinomycetes were tested for the 
requirement of seawater for growth. Fresh Salinispora-
like actinomycetes’ colonies were streaked on A1 agar 
plate prepared with seawater and a plate prepared with 
filtered distilled water. Growth was monitored on both 
plates visually and with the aid of a stereomicroscope 
for up to 4 weeks. If no growth was observed on the plate 
prepared with filtered distilled water, that strain was 
determined to require seawater for growth.
2.5. Bioassay and selection of potential strain  
   All the isolated Salinispora strains were subjected 
for small scale fermentation by inoculating each strain in 
100 mL A1B medium (1 g of starch, 0.4 g of yeast extract, 
0.2 g of peptone) incubating at 28 °C in temperature 
controlled incubator at 200 r/min for 7-14 d. After 
incubation, the whole cultures (100 mL) were extracted 
twice with equal volumes of ethyl acetate (EtOAc) using 
a separating funnel. The EtOAc crude extract was dried 
in vacuo using rotary evaporator under 35 °C. Each crude 
extract of the strains was tested for bioassay against 
methicillin-resistant Staphylococcus aureus (S. aureus) 
(MRSA), wild type S. aureus (WTSA), vancomycin-resistant 
Enterococcus faecium (E. faecium) (VREF), amphotericin 
resistant Candida albicans (C. albicans) and wild type 
C. albicans at 250 µg/disc concentration. The highest 
bioactivity displayed strain was selected for mass 
production in order to produce enough metabolites for 
purification of bioactive compounds. 
2.6. Extraction and isolation
   Salinispora sp. FS-0034 was cultured in 24 Fernbach 
flasks (2.8 L) each containing 1 L of a natural seawater-
based A1B medium. The whole culture broth along with 
cells was extracted twice with EtOAc by sonication 
for 20-30 min. The EtOAc phase was concentrated in 
vacuo to give a crude extract (2.77 g). The crude EtOAc 
extract was subjected to normal phase vacuum liquid 
chromatography with mixtures of direct-current main 
and MeOH in gradually increasing the polarity. A total of 
eleven fractions were obtained which were subjected to 
bioassay. All the fractions showed activity against MRSA, 
WTSA and VREF. However, fraction three (FS-0034F3) 
was selected for further purification based on higher 
bioactivity and quantity. FS-0034F3 was subjected to RP 
C18 column chromatography using mixtures of MeOH/H2O. 
A total of sixteen fractions were collected and pooled to 
three fractions (FS-0034F3F1 to FS-0034F3F3) based on the 
profiles on TLC. Fraction FS-0034F3F1 was further selected 
for purification by RP C18 column chromatography based 
on the bioactivity. Totally, ten fractions were collected; 
bioactive fractions (FS-0034F3F1F6 and FS-0034F3F1F7) 
were further purified by RP (Zorbax ODS 5 µm 9.4 mm伊250 
mm column) semi-preparative Waters 515 HPLC system 
yielding a pure bright red powder (compound 1; 2.1 mg). 
   Rifamycin W (compound 1): Bright red powder, UV 
(MeOH) λmax 230, 275, and 325 nm; molecular formula 
C35H45NO11; HRESIMS (m/z): 656.3068 [M+H]
+ (calcd. for 
C35H46NO11, 656.3065); 
1
H NMR, correlated spectroscopy 
(COSY) and heteronuclear multiple-bond correlation 
(HMBC) spectroscopic data, see Table 1.
Table 1 
NMR chemical shifts (600 MHz, dimethylsulfoxide-d6) for rifamycin W.
Position δH (multi, J in Hz) COSY HMBC
b
NH 9.50
H-3 7.47 s 127.6 (C10), 140.6 (C2), 182.6 (C1)
H-13 2.02 s 132.9 (C12), 169.9 (C11), 131.2 (C29)
H-14 2.14 s 116.9 (C7 ), 159.9 (C6), 161.5 (C8)
H-17 6.20 ovl H18
H-18 6.31 m H17
H-19 6.00 dd (15.8, 6.0) H20
H-20 2.22 m H19, H21, H31
H-21 3.99 m H22, H20
H-22 1.96 m H32
H-23 3.56 m H22, H24
H-24 1.51 m H23, H33
H-25 3.67 m H26
H-26 1.19 m H34, H25
H-27 3.18 m H28
H-28 3.31a H27, H34a
H-29 6.196 ovl H28
H-30 1.94 s 196.0 (C15), 137.6 (C17), 139.5 (C16)
H-31 0.84 d (6.86) H20 36.4 (C20), 71.2 (C21),
H-32 0.87 d (7.04) H22 29.5 (C22), 76.9 (C23)
H-33 0.62 d (6.80) H24 76.9 (C23 ), 67.9 (C25), 37.5 (C24)
H-34 0.17 d (6.82) H26 67.9 (C25), 65.4 (C27), 41.9 (C28), 39.7 (C26)
H-34a 2.39 m 
ovl: Overlap; a: Signal hidden by solvent peak in 1H NMR (obtained 
from COSY); b: Tentative assignments.
2.7. Antibacterial assay
   The minimum inhibitory concentrations (MICs) of 
compound 1 against different test organisms were 
determined by the broth dilution method[15]. The isolated 
compound 1 was dissolved in MeOH at 10 mg/mL and 
diluted further to give required concentrations (µg/
mL) 500.00, 250.00, 125.00, 62.50, 31.25, 15.62, 7.80, 3.90, 
1.90, 0.97, 0.48, 0.24, 0.12, 0.06, 0.03 and 0.01. The diluted 
solutions (100 µL) were added to separate wells on a 96 
wells plate. An inoculum of 100 µL from 24 h old culture 
of each test human pathogens, MRSA (ATCC 10537), WTSA 
and  VREF (ATCC 12952) were inoculated separately in each 
well. The antibacterial agents vancomycin (MRSA and 
WTSA) and rifampicin (Voltage Reference VREF) were used 
as positive controls and the solvent MeOH was included 
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in the bioassay as negative control. The cultures were 
incubated for 24 h at 37 °C. Replicates were performed 
for each treatment. The MIC was defined as the lowest 
concentration of the pure compound/antibiotics showing 
no visible growth after the incubation time. 
3. Results 
   A  to ta l  o f  e ighteen Sal in i spora  s t ra ins  were 
isolated from the sponge tissues of Theonella sp. The 
characteristics of obligatory growth in seawater based 
medium and colony morphology confirmed the isolates as 
Salinispora spp. Further all the Salinispora strains were 
subjected for bioassay against drug-resistant pathogens. 
All the eighteen strains displayed activity against MRSA 
and WTSA with fourteen strains active against VREF. The 
strain FS-0034 exhibited highest antibacterial activity 
against multi-drug resistant human pathogens (Table 2). 
Table 2 
Screening of marine-sponge-derived Salinispora sp. against multi-
drug resistant human pathogens (zone of inhibition in mm; 250 µg/
disc).
Strains
Seawater 
requirement
Antibacterial Antifungal
MRSA WTSA VREF ARCA WTCA
FS-0028 + 20 18 10 - -
FS-0029 + 16 17 11 - -
FS-0030 + 29 27 10 - -
FS-0031 + 18 16 10 - -
FS-0032 + 20 16 10 - -
FS-0033 + 28 29 11 - -
FS-0034 + 30 30 14 - -
FS-0035 + 30 30 13 - -
FS-0036 + 17 18 - - -
FS-0037 + 20 18 10 - -
FS-0038 + 18 16 9 - -
FS-0039 + 20 21 - - -
FS-0040 + 30 30 12 - -
FS-0041 + 17 18 10 - -
FS-0042 + 23 22 - - -
FS-0043 + 16 16 9 - -
FS-0044 + 30 29 10 - -
FS-0045 + 28 29 - - -
Control 19 19 22 25 25
MRSA: Methicillin-resistant S. aureus; WTSA: Wild type S. 
aureus; VREF: Vancomycin-resistant Enterococcus faecium; 
ARCA: Amphotericin resistant C. albicans; WTCA: Wild type C. 
albicans.
 
   The Salinispora sp. FS-0034 was mass cultivated (24 L) 
in seawater based A1 medium for 14 d at 28 °C in shaking 
incubator at 200 r/min. After 14 days of growth in A1 broth, 
the total culture medium was extracted with EtOAc and 
concentrated in vacuo to give a crude extract (2.77 g). The 
crude extract (active against MRSA, WTSA and VREF) was 
fractionated by using different chromatography (Figure 
1) yielded a metabolite as pure red powder (compound 1; 
2.1 mg). The pure compound was further subjected to RP 
analytical HPLC (Zorbax ODS 5.00 µm 4.60 mm伊250.00 mm) 
to analyze the purity and further submitted for NMR and 
other spectroscopic studies for structure elucidation.
Salinispora sp.FS-0034
Sonication EtOAc extraction
Bioassay
Crude EtOAc extract
VLC
F3F1
Bright red powder
Semi-preparative HPLC
F3F2 F3F3RP-Silica gel 
[10-100% MeOH(aq)]
Silica gel; (DCM/MeOH)
F1         F2        F3        F4        F5         F6          F7         F8       F9        F10           F11
F1         F2           F3          F4           F5           F6         F7           F8        F9         F10
F1        F2      F3      F4       F5      F6      F7      F8       F9       F10    F11     F12    F13     F14     F15    F16
RP-Silica gel; [10-100% MeOH(aq)]
Figure 1. Schematic diagram of procedure for isolation of compound 1.
   Compound 1 was obtained as bright red powder. 
Its molecular formula C35H45NO11 was established by a 
pseudomolecular ion at [M+H]+ m/z 656.3068 from high 
resolution electrospray ionization mass spectroscopy [(M+H)+; 
calcd for C35H46NO11 m/z 656.3065) (Figure 2). Compound 1 also 
showed characteristic UV absorption maxima at 230, 275 and 
325 nm suggesting a naphthoquinone nucleus chromophore. 
Further, AntiBase (2012) search for the corresponding 
molecular mass together with the given UV maxima and 
the single aromatic proton from 1H NMR spectrum revealed 
a match to the known rifamycin W. In addition, the 1H 
NMR, COSY and HMBC experiments assisted to establish the 
structure of compound 1. The 1H NMR spectrum of compound 
1 showed two downfield singlets at δ 7.47 ppm and δ 9.50 
ppm, the latter representing the amine proton while the 
former representing the single aromatic proton. The up-field 
region of the 1H NMR spectrum revealed a total of seven methyl 
signals from which four signals were present as doublets 
and three as singlets. Furthermore, the methyls at H3-31, 
H3-32, H3-33 and H3-34 showed COSY correlations to the 
corresponding methines at H-20 (δ 2.22 ppm), H-22 (δ 1.96 
ppm), H-24 (δ 1.51 ppm) and H-26 (δ 1.19 ppm), respectively. 
Moreover, the methine proton H-20 showed further COSY 
to the olefinic proton H-19 (δ 6.00 ppm) and methine H-21 
(δ 3.99 ppm). The olefins H-17 and H-18 were overlapped 
in the 1H NMR spectrum while olefin H-29 showed COSY to 
H-28 as H-28 showed COSY to H-34a. The COSY spectrum 
also displayed other methine-methyl and methine-
methine correlations as given in Figure 3. In addition, the 
carbon values were tentatively assigned by comparison to 
the literature[16]. Supportively, HMBC correlations (Figure 
4) confirm the correct assignments of the methyls and the 
aromatic proton, further affirming the proposed structure for 
compound 1 to be rifamycin W. 
   Rifamycin W (compound 1) showed appreciable antibacterial 
activity against MRSA, WTSA and VREF exhibiting MICs of 
15.62, 7.80 and 250.00 µg/mL, respectively.
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Figure 3. COSY correlations of compound 1.
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Figure 4. COSY and HMBC correlations of compound 1.
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4. Discussion
   Novel  Actinobacteria with biopharmaceutical 
potential have been increasingly isolated from marine 
habitats[10,14,17]. The Salinispora group, as a relatively 
newly discovered group of Actinobacteria have been 
found in diverse habitats such as marine sediments 
and marine sponges[14,17,18]. The marine actinomycete 
genus Salinispora is composed of three closely related 
species (Salinispora arenicola, Salinispora pacifica 
and Salinispora tropica) that have been identified so 
far[19]. These bacteria have proven to be a rich source of 
secondary metabolites, which are produced in species-
specific patterns that include antibacterial, potent 
cytostatic, anticancer, antimalarial and proteasome 
inhibitor activities[9,10]. In the present study, eighteen 
strains were isolated and confirmed as Salinispora 
strains due to its stringent requirement of seawater for 
growth and other morphological characteristics[13,14]. All 
isolated strains in the present study showed significant 
antibacterial activity against multi-drug resistant 
pathogens. Among them, a highest bioactivity showing 
Salinispora sp. FS-0034 was subjected to production and 
purification of bioactive compounds yielding the strong 
MRSA and VREF active rifamycin W.
   Rifamycins, a group of antibiotics of the ansamycin 
family[20], are clinically important antibacterial agents 
active against Gram-positive bacteria. Several semi-
synthetic rifamycin variants (e.g., rifampin) have been 
used clinically for the treatment of tuberculosis and 
other bacterial infections, but resistance threatens their 
Figure 2. High resolution electron spray ionization mass spectroscopy of compound 1.
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effectiveness[21]. Rifamycins are known to be produced 
by the soil actinobacterial species Amycolatopsis 
mediterranei and Nocardia mediterranei and rifamycin 
synthesis has been most intensively studied in these 
species[22,23]. The gene cluster for the biosynthesis 
of rifamycin B, a compound forming the basis for all 
other rifamycins, has been characterized only in 
Amycolatopsis mediterranei[22,23]. However it has recently 
been reported that members of marine genus Salinispora 
are known to produce compounds of the rifamycin 
class, including rifamycin B and rifamycin SV[18,24]. In 
the present study we reported rifamycin W from the 
Salinispora sp. FS-0034. Rifamycin W was previously 
isolated from the fermentation medium of the mutant 
strain Nocardia mediterranei[16]. Therefore, the marine 
obligate Salinispora group of actinobacteria represents 
a potential new source of rifamycins outside the soil 
genera Amycolatopsis and Nocardia. Further, the present 
study has added strength to the biological properties of 
rifamycin W as it was showed strong antibacterial activity 
against multi-drug resistant human pathogens.    
   Herein we report the isolation of rifamycin W from a 
sponge-associated Salinispora sp. and describe its strong 
antibacterial activity against multi-drug resistant human 
pathogens including MRSA, WTSA and VREF. The consistent 
production of specific classes of secondary metabolites 
by Salinispora species will raise the expectancy in this 
group to discover novel drug leads. 
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Comments 
Background
   The increasing emergence of multi-drug resistant 
human pathogens is seriously limiting the effectiveness 
of currently available drugs and significantly causing 
treatment failure. The ocean is an important source of 
bioactive substances and numerous antibiotics derived 
from the marine play a significant role in the treatment 
of many diseases. The search for new and innovative 
antimicrobial agents has become an urgent issue facing 
humanity.
  
Research frontiers
   In the present study, the authors isolated a bioactive 
compound, rifamycin W, from sponge-associated 
Salinispora sp. using various spectrum analysis methods 
and examined its appreciable antibacterial activity 
against multi-drug resistant human pathogens by MIC 
assays.
Related reports
   This study also provided the specific information about 
the rifamycin W, including the molecular formula and the 
molecular structure using various spectral analysis of UV, 
HRESIMS, 1H NMR, COSY and HMBC spectral data.
Innovations and breakthroughs
   Recently members of marine genus Salinispora 
are reported to produce compounds of the rifamycin 
class, including rifamycin B and rifamycin SV. In the 
present study, the authors isolated rifamycin W from 
the Salinispora sp. with strong antibacterial activity, 
showing that the marine obligate Salinispora group of 
actinobacteria can represent a potential new source of 
rifamycins.
  
Applications
   The research work illustrated the strong antibacterial 
activity of rifamycin W (compound 1) against multi-drug 
resistant human pathogens, indicating that secondary 
metabolites from Salinispora species have potential to be 
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developed as novel antibacterial agents.    
Peer review
   This is a good research paper in which the authors 
obtained rifamycin W (compound 1) from the EtOAc 
extract of the culture of Salinispora sp. FS-0034 and 
found that it had potent antibacterial activity. The results 
are meaningful and valuable and lay a solid foundation 
for further studies.
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